Cryptic chromosomal aberrations leading to an AML1/ETO rearrangement are frequently caused by small insertions - PubMed (original) (raw)
Case Reports
doi: 10.1002/gcc.10168.
Affiliations
- PMID: 12557226
- DOI: 10.1002/gcc.10168
Case Reports
Cryptic chromosomal aberrations leading to an AML1/ETO rearrangement are frequently caused by small insertions
Ulrike Gamerdinger et al. Genes Chromosomes Cancer. 2003 Mar.
Abstract
The translocation t(8;21)(q22;q22), which results in the fusion of the AML1 (RUNX1) and ETO (CBFA2T1) genes, is a recurrent aberration in acute myeloid leukemia (AML), preferentially correlated with FAB M2, and has the highest incidence in childhood AML. Because of the favorable prognosis, the evidence of the t(8;21) or the AML1/ETO fusion gene is mandatory in most of the therapy trials, allowing the stratification of the patients to the correct risk group in terms of treatment. Here we present six out of 59 children with AML who were positive for AML1/ETO by RT-PCR, but showed no evidence of the classical t(8;21)(q22;q22) by conventional cytogenetics. Because of the discrepancies between molecular and cytogenetic analyses, these six patients were further investigated by fluorescence in situ hybridization analysis. Small hidden interstitial insertions resulting in an AML1/ETO rearrangement were detected in five (8.5%) of the 59 patients, whereas the sixth patient showed a cryptic three-way translocation. The insertions could be characterized as ins(21;8) in three patients and ins(8;21) in the remaining two. Additionally, three of the patients showed secondary chromosome aberrations leading to a higher complexity of the karyotype. In conclusion, the combination of more than one standard technique in the analysis of AML1/ETO is useful to reveal the overall frequency of cryptic chromosome rearrangements and permits a better understanding of the mechanisms involved in the generation of this fusion gene.
Copyright 2003 Wiley-Liss, Inc.
Similar articles
- Insertions generating the 5'RUNX1/3'CBFA2T1 gene in acute myeloid leukemia cases show variable breakpoints.
Specchia G, Albano F, Anelli L, Zagaria A, Liso A, La Starza R, Mancini M, Sebastio L, Giugliano E, Saglio G, Liso V, Rocchi M. Specchia G, et al. Genes Chromosomes Cancer. 2004 Sep;41(1):86-91. doi: 10.1002/gcc.20061. Genes Chromosomes Cancer. 2004. PMID: 15236320 - Fluorescence in situ hybridization study of TEL/AML1 fusion and other abnormalities involving TEL and AML1 genes. Correlation with cytogenetic findings and prognostic value in children with acute lymphocytic leukemia.
Martínez-Ramírez A, Urioste M, Contra T, Cantalejo A, Tavares A, Portero JA, López-Ibor B, Bernacer M, Soto C, Cigudosa JC, Benítez J. Martínez-Ramírez A, et al. Haematologica. 2001 Dec;86(12):1245-53. Haematologica. 2001. PMID: 11726315 - PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22).
Zhang Y, Emmanuel N, Kamboj G, Chen J, Shurafa M, Van Dyke DL, Wiktor A, Rowley JD. Zhang Y, et al. Genes Chromosomes Cancer. 2004 Aug;40(4):365-70. doi: 10.1002/gcc.20050. Genes Chromosomes Cancer. 2004. PMID: 15188461 - [The role of TEL and AML1 genes in the pathogenesis of hematologic malignancies].
Zuna J. Zuna J. Cas Lek Cesk. 2001 Mar 15;140(5):131-7. Cas Lek Cesk. 2001. PMID: 11347199 Review. Czech. - AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.
Licht JD. Licht JD. Oncogene. 2001 Sep 10;20(40):5660-79. doi: 10.1038/sj.onc.1204593. Oncogene. 2001. PMID: 11607817 Review. No abstract available.
Cited by
- Fusion Gene-Based Classification of Variant Cytogenetic Rearrangements in Acute Myeloid Leukemia.
Gudipati M, Butler M, Koka R, Baer MR, Ning Y. Gudipati M, et al. Genes (Basel). 2023 Feb 3;14(2):396. doi: 10.3390/genes14020396. Genes (Basel). 2023. PMID: 36833323 Free PMC article. - Cytogenetics of Pediatric Acute Myeloid Leukemia: A Review of the Current Knowledge.
Quessada J, Cuccuini W, Saultier P, Loosveld M, Harrison CJ, Lafage-Pochitaloff M. Quessada J, et al. Genes (Basel). 2021 Jun 17;12(6):924. doi: 10.3390/genes12060924. Genes (Basel). 2021. PMID: 34204358 Free PMC article. Review. - Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia.
Mrózek K, Marcucci G, Paschka P, Bloomfield CD. Mrózek K, et al. Curr Opin Oncol. 2008 Nov;20(6):711-8. doi: 10.1097/CCO.0b013e32831369df. Curr Opin Oncol. 2008. PMID: 18841055 Free PMC article. Review. - Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Mrózek K, et al. Blood. 2007 Jan 15;109(2):431-48. doi: 10.1182/blood-2006-06-001149. Epub 2006 Sep 7. Blood. 2007. PMID: 16960150 Free PMC article. Review.